May 2nd 2024
During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
ESMO 2022: New Combinations and Settings in RCC Show Mixed Results
October 19th 2022Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.
Read More
Discussing Real-World Experience Using Lenvatinib in Advanced RCC
October 14th 2022During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed with participants their experiences using lenvatinib in treatment of advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Efficacy and Quality of Life Data from 5-Year Follow-Up of CheckMate 214
October 14th 2022Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Watch
Comparing Physician Experience With Trial Data for Frontline RCC Regimens
October 3rd 2022During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.
Read More
Risk Stratification for Patients with Advanced Renal Cell Carcinoma
September 30th 2022An expert oncologist explains how to calculate a patient’s risk status and provides an overview of front-line treatment options for patients with advanced renal cell carcinoma and discusses which factors are considered when choosing appropriate treatment.
Watch